The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

The Overview of Endocrine Hypertension

내분비 고혈압의 개요

  • Lee, Hye-Jin (Division of Endocrinology and Metabolism, Department of Internal Medicine, Ewha Womans University School of Medicine)
  • 이혜진 (이화여자대학교 의학전문대학원 내분비내과학교실)
  • Published : 2012.04.01
⟨ Previous Next ⟩

Abstract

The prevalence of hypertension is approximately 30%. Hypertension is a major risk factor for stroke, ischemic heart disease and cardiac failure. In most, hypertension is essential or idiopathic, but a subgroup of approximately 15% has secondary hypertension. Endocrine hypertension is one of the common causes of secondary hypertension and is characterized by hormonal derangements. There are at least 14 endocrine disorders for which hypertension may be the initial clinical presentation. An accurate diagnosis of endocrine hypertension provides the clinician with a unique treatment opportunity. Therefore understanding about the appropriate diagnosis and management is very important.

Keywords

References

  1. Sukor N. Endocrine hypertension: current understanding and comprehensive management review. Eur J Intern Med 2011;22:433-440. https://doi.org/10.1016/j.ejim.2011.05.004
  2. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571-1576. https://doi.org/10.1001/jama.1996.03530440051036
  3. Baruah MP, Kalra S, Unnikrishnan AG. Endocrine hypertension: changing paradigm in the new millennium. Indian J Endocrinol Metab 2011;15(Suppl 4):S275-S278. https://doi.org/10.4103/2230-8210.86858
  4. Faselis C, Doumas M, Papademetriou V. Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens 2011;2011:236-239.
  5. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006;48:2293-2300. https://doi.org/10.1016/j.jacc.2006.07.059
  6. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004;89:1045-1050. https://doi.org/10.1210/jc.2003-031337
  7. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1983;58:802-804.
  8. Stewart BH, Bravo EL, Meaney TF. A new simplified approach to the diagnosis of pheochromocytoma. J Urol 1979;122:579-581. https://doi.org/10.1016/S0022-5347(17)56513-1
  9. Sukor N. Secondary hypertension: a condition not to be missed. Postgrad Med J 2011;87:706-713. https://doi.org/10.1136/pgmj.2011.118661
  10. Schwartz GL. Screening for adrenal-endocrine hypertension: overview of accuracy and cost-effectiveness. Endocrinol Metab Clin North Am 2011;40:279-294. https://doi.org/10.1016/j.ecl.2011.02.001
  11. Young WF Jr. Endocrine hypertension: then and now. Endocr Pract 2010;16:888-902. https://doi.org/10.4158/EP10205.RA
  12. Anagnostis P, Karagiannis A, Tziomalos K, Athyros VG, Kita M, Mikhailidis DP. Endocrine hypertension: diagnosis and management of a complex clinical entity. Curr Vasc Pharmacol 2010;8:646-660. https://doi.org/10.2174/157016110792006996
  13. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. Williams Textbook of Endocrinology. 12th ed. Philadelphia: Elsevier/Saunders, 2011.
  14. Nimkarn S, New MI. Steroid 11beta-hydroxylase deficiency congenital adrenal hyperplasia. Trends Endocrinol Metab 2008;19:96-99. https://doi.org/10.1016/j.tem.2008.01.002
  15. Wang W, Fu JF, Gong FQ, Zhu WH, Shen Z. Rare hypertension as a result of 17alpha-hydroxylase deficiency. J Pediatr Endocrinol Metab 2011;24:333-337.
  16. Scacchi M, Cavagnini F. Acromegaly. Pituitary 2006;9:297-303. https://doi.org/10.1007/s11102-006-0409-4